Table S1: Basic and Clinical characteristics of stage III GC patients treated and not treated by MDT intervention.

| Characteristics | Non-MDT (n=122) | MDT (n=172) | *p* |
|---|---|---|---|
| **Age (years)** | | | |
| < 60 | 67 (54.9) | 105 (61.0) | 0.293 |
| ≥ 60 | 55 (45.1) | 67 (39.0) | |
| **Sex** | | | |
| Men | 84 (68.9) | 109 (63.4) | 0.330 |
| Women | 38 (31.1) | 63 (36.6) | |
| **Primary tumor site** | | | |
| Upper | 41 (33.6) | 69 (40.1) | 0.211 |
| Middle | 27 (22.1) | 47 (27.3) | |
| Lower | 49 (40.2) | 49 (28.5) | |
| Whole | 5 (4.1) | 7 (4.1) | |
| **Radical resection** | | | |
| No | 14 (11.5) | 22 (12.8) | 0.735 |
| Yes | 108 (88.5) | 150 (87.2) | |
| **cT stage** | | | |
| T1 + T2 | 2 (1.6) | 4 (2.3) | 0.000*** |
| T3 | 81 (66.4) | 73 (42.4) | |
| T4 | 39 (32.0) | 95 (55.2) | |
| **cN stage** | | | |
| N0 | 4 (3.3) | 27 (15.7) | 0.000*** |
| N1 | 13 (10.7) | 24 (14.0) | |
| N2 | 73 (59.8) | 54 (31.4) | |
| N3 | 32 (26.2) | 67 (39.0) | |
| **Differentiation** | | | |
| Moderate | 23 (18.9) | 46 (26.7) | 0.116 |
| Poor | 99 (81.1) | 126 (73.3) | |
| **Borrmann type** | | | |
| I + II | 22 (18.0) | 37 (21.5) | 0.463 |
| III + IV | 100 (82.0) | 135 (78.5) | |
| **CEA (ug/L)** | | | |
| ≤ 5 | 84 (68.9) | 131 (76.2) | 0.164 |
| > 5 | 38 (31.1) | 41 (23.8) | |

* p<0.05, ** p<0.01, *** p<0.001; MDT: multidisciplinary team; CEA: carcinoembryonic antigen

**Table S2.** Basic and Clinical characteristics of stage IV GC patients treated and not treated MDT intervention

| Characteristics | Non-MDT (n=40) | MDT (n=60) | *p* |
|---|---|---|---|
| **Age (years)** | | | |
| < 60 | 26 (65.0) | 38 (63.3) | 0.865 |
| ≥ 60 | 14 (35.0) | 22 (36.7) | |

| | | | |
|---|---|---|---|
| **Sex** | | | |
| Men | 24 (60.0) | 37 (61.7) | 0.867 |
| Women | 16 (40.0) | 23 (38.3) | |
| **Primary tumor site** | | | |
| Upper | 6 (15.0) | 16 (26.7) | 0.236 |
| Middle | 14 (35.0) | 15 (25.0) | |
| Lower | 13 (32.5) | 24 (40.0) | |
| Whole | 7 (17.5) | 5 (8.3) | |
| **Radical resection** | | | |
| No | 9 (22.5) | 15 (25.0) | 0.774 |
| Yes | 31 (77.5) | 45 (75.0) | |
| **cT stage** | | | |
| T1 + T2 | 2 (5.0) | 1 (1.7) | 0.001** |
| T3 | 25 (62.5) | 17 (28.3) | |
| T4 | 13 (32.5) | 42 (70.0) | |
| **cN stage** | | | |
| N0 | 1 (2.5) | 5 (8.3) | 0.484 |
| N1 | 10 (25.0) | 6 (10.0) | |
| N2 | 11 (27.5) | 11 (18.3) | |
| N3 | 18 (45.0) | 38 (63.3) | |
| **Differentiation** | | | |
| Moderate | 7 (17.5) | 13 (21.7) | 0.610 |
| Poor | 33 (82.5) | 47 (78.3) | |
| **Borrmann type** | | | |
| I + II | 6 (15.0) | 8 (13.3) | 0.814 |
| III + IV | 34 (85.0) | 52 (86.7) | |
| **CEA (ug/L)** | | | |
| ≤5 | 27 (67.5) | 42 (70.0) | 0.828 |
| >5 | 13 (32.5) | 18 (30.0) | |

* p<0.05, ** p<0.01, *** p<0.001; MDT: multidisciplinary team; CEA: carcinoembryonic antigen